Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési(Aix-Marseille Université), Daniel Waterkamp, Keunchil Park(Samsung Medical Center), Fortunato Ciardiello(University of Naples Federico II), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Shirish M. Gadgeel(The Barbara Ann Karmanos Cancer Institute), Toyoaki Hida(Aichi Cancer Center), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Manuel Cobo(Hospital Regional Universitario de Málaga), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Joseph W. Leach(Minnesota Oncology), Jonathan Polikoff, Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul), Fairooz F. Kabbinavar(University of California, Los Angeles), Osvaldo Arén Frontera(Centro de Estudios Científicos), Filippo de Marinis(European Institute of Oncology), Hande Turna(Istanbul University), Jong-Seok Lee(Seoul National University Bundang Hospital), Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara(University of California, Davis)
Cited by 4,761Open Access